Rachel Haurwitz

Notable Quotes

Selection of both of Caribou's allogeneic CAR-T cell programs as late-breaking presentations underscores the strength of the safety, efficacy, and durability data and the potential impact these off-the-shelf CAR-T cell therapies can have in addressing urgent patient need. — February 2026, on Tandem Meetings presentation

from Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments · Updated May 30

Stories

Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments

New Capabilities

Leading CB-011 through accelerated FDA pathway

Every approved cancer cell therapy today requires extracting a patient's own cells, engineering them in a lab, and infusing them back. It costs over $400,000 and sometimes takes weeks — long enough that patients' cancer can grow while they wait.

Updated May 30

Rachel Haurwitz

Notable Quotes

Stories

Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments

Help us improve Newzino